OMNY Health expands real-world data ecosystem with new GLP-1 data network

OMNY Health’s new GLP-1 data network enhances clinical research by integrating real-world data (RWD) from electronic health record (EHR) data of 645,000 patients, advancing insights into diverse populations and improving healthcare outcomes.

OMNY Health, a national healthcare data ecosystem, has announced the launch of its glucagon-like peptide-1 (GLP-1) data network, an initiative designed to enhance clinical research and improve patient care. The network integrates EHR data from over 645,000 patients, offering life sciences companies, health systems, and AI-driven health tech partners valuable insights into the use of GLP-1 therapies, particularly within diverse populations. This launch is part of OMNY Health’s broader data ecosystem, which now encompasses over 2 billion clinical notes from more than 300,000 providers across 200+ specialties.

GLP-1 therapies are recognized as effective treatments for managing conditions such as type 2 diabetes and obesity, with their application extending to other chronic conditions, including cardiovascular disease, liver disease, and skin disorders. Despite the increasing use of these medications, a significant portion—97%—of healthcare data remains underutilized, limiting the comprehensive evaluation of GLP-1 therapies. OMNY Health’s GLP-1 network seeks to address this issue by providing detailed data to assess the effectiveness and long-term outcomes of these treatments across various patient demographics.

“GLP-1 therapies are transforming the treatment landscape across multiple conditions beyond diabetes and obesity in profound ways. The systemic impact of these medications underlines the need for more comprehensive data to fully understand how these therapies affect patients as a whole. By democratizing data partnerships between life sciences companies and health systems, we can enable more in-depth clinical research that will fuel healthcare innovation and revolutionize the potential impact of GLP-1’s for years to come.” Dr. Mitesh Rao, CEO, OMNY Health.

The network’s data, curated from a diverse patient population, supports studies that aim to close gaps in understanding GLP-1 therapies. This includes research on their use in pediatric populations and among patients affected by social determinants of health (SDOH). OMNY Health’s data network revealed that patients using GLP-1 therapies were half as likely to experience economic insecurity, food insecurity, or social isolation compared to non-users, according to their EHR. This highlights the importance of considering SDOH factors in clinical research to better understand and address health disparities.

“We are able to deliver more equitable clinical outcomes when the research is backed by data from diverse populations,” said Dr. Sameer Badlani, Fairview Health Services’ Executive Vice President, and Chief Strategy Officer. “With access to data that factors in SDOH for diverse populations we learn valuable insights in service of providing resources and clinical care that is differentiated by excellence in quality, safety, experience and health equity for every consumer who trusts us with their wellness and care.”